Predictive Biomarkers for PD-1 Inhibitor Response in Squamous Cell Carcinoma

• Study Title Biomarkers for Predicting Response to PD-1 Inhibitor Therapy in Squamous Cell Carcinoma: A Retrospective-Prospective Cohort Study
• Background and Rationale Squamous Cell Carcinoma (SCC) is a malignancy arising from squamous epithelium, affecting multiple organs including the skin, oral cavity, esophagus, lungs, and cervix. It is characterized by a high incidence rate and significant mortality.

• Epidemiology of SCC Subtypes:
• Esophageal Squamous Cell Carcinoma (ESCC): According to 2022 GLOBOCAN data, esophageal cancer is the 11th most common cancer globally, with ESCC accounting for approximately 90% of cases. China is a high-incidence region for this disease. Despite a decreasing incidence, the five-year survival rate remains low at around 20%.
• Head and Neck Squamous Cell Carcinoma (HNSC): HNSC represents about 90% of all head and neck cancers, with approximately 890,000 new cases and 325,000 deaths globally in 2022. In China, the mortality rate from head and neck cancer has been rising, primarily linked to risk factors like smoking, alcohol consumption, and betel nut use.
• Cervical Squamous Cell Carcinoma (CESC): In 2022, China recorded the highest number of new cervical cancer cases globally, with 150,659 new diagnoses (23% of the global total) and 55,694 deaths (16% of the global total). Disparities in screening and HPV vaccination access contribute to a heavy burden, particularly in lower-income areas.
• Lung Squamous Cell Carcinoma (LUSC): In 2022, China accounted for 42.8% of new global lung cancer cases and 40.3% of deaths. LUSC is a major subtype, strongly associated with smoking, and is characterized by rapid cell proliferation and a high potential for invasion and metastasis.

• Therapeutic Landscape and Unmet Needs: The advent of PD-1 inhibitors over the past decade has offered new hope for patients with SCC. However, clinical trials have shown that the benefits are limited to a subset of patients, and the high cost of treatment places a significant financial burden on healthcare systems. Therefore, there is a critical need to develop accurate and reliable predictive biomarkers to identify patients most likely to respond to immunotherapy.
• Current Biomarkers and Rationale for a Pan-SCC Approach: PD-L1 expression is the most widely studied biomarker, assessed via systems like Tumor Proportion Score (TPS) and Combined Positive Score (CPS). However, these methods have limitations. This study is founded on the principle that SCCs originating from different anatomical sites (esophagus, cervix, head and neck, lung) share significant molecular and immunological similarities. This "pan-cancer" approach allows for the integration of data across tumor types to identify common biological characteristics and universal mechanisms of drug resistance. By expanding from a single cancer type to a pan-SCC analysis, this study aims to accelerate the optimization of immunotherapy strategies and develop a more broadly applicable predictive model. Within this framework, assay-based biomarker features, including blood ELISA and tissue mIF, and pretreatment tissue-pathology features, including PD-L1 assessment, biopsy/H&E-based features, and other clinicopathological features where available, may be evaluated as component scores and/or integrated risk scores to support response prediction and risk stratification.

This innovative retrospective-prospective cohort study will integrate real-world clinical data with biological samples to build and validate a predictive model specifically for Chinese patients with SCC, aiming to guide clinical decision-making and optimize resource allocation.

• Study Objectives

• Primary Objective: To evaluate the performance of a predictive model or risk-score framework based on blood-based ELISA, tissue-based multiplex immunofluorescence assays, PD-L1 assessment, and available pretreatment biopsy/H&E-based pathology and clinicopathological features, individually or in combination, in forecasting the efficacy of PD-1 inhibitor-based therapy in patients with squamous cell carcinoma.
• Secondary Objectives:

<!-- -->

• To develop and evaluate component or integrated predictive scores using data from blood ELISA, tissue multiplex immunofluorescence, PD-L1 assessment, and available pretreatment biopsy/H&E-based pathology and clinicopathological features.
• To stratify patients into different risk groups based on the model's predictions.
• To analyze and compare treatment-response and survival outcomes (e.g., survival curves, duration of response, PFS, EFS, and OS) among the different patient risk groups.
• Study Design This is a multi-center, cohort study with both retrospective and prospective components.

• 1) Retrospective Cohort (from May 2020 onward): This phase involves the collection of baseline information, clinical data, and pre-treatment tumor biopsy, H&E slides where available, and blood samples from SCC patients who received PD-1 inhibitor-based therapy at the participating centers. Data will be used to develop and refine an initial predictive model or risk-score framework by correlating blood-based, tissue-based, and clinicopathological features with clinical outcomes such as Objective Response Rate (ORR), pathological response where applicable, Duration of Response (DoR), Progression-Free Survival (PFS), Event-Free Survival (EFS), Overall Survival (OS), and other treatment-response outcomes to assess the model's feasibility.
• 2) Prospective Cohort (Starting September 2025):

This phase begins in September 2025 and aims to enroll up to 800 participants to validate the predictive model or risk-score framework developed from the retrospective data. Patients may include those receiving PD-1 inhibitor therapy with or without chemotherapy, including disease-specific cohorts receiving neoadjuvant anti-PD-1 therapy plus chemotherapy where applicable, and will be stratified according to the model's risk score, based on:

• High risk of treatment resistance as indicated by the combined biomarker or tissue-based scoring system.
• Low risk of treatment resistance as indicated by the same scoring system. 5. Study Population

• Inclusion Criteria:
• Pathologically confirmed diagnosis of Esophageal (ESCC), Head and Neck (HNSC), Cervical (CESC), or Lung (LUSC) squamous cell carcinoma.
• Patients scheduled to receive PD-1 inhibitor therapy ± chemotherapy, either as neoadjuvant treatment (for operable cases) or first-line systemic therapy (for inoperable cases).
• Availability of pre-treatment tumor biopsy tissue, corresponding H&E slides where applicable, baseline blood samples where available, and baseline clinicopathological data.
• Age ≥ 18 years.
• Capacity to provide written informed consent.

• Exclusion Criteria:

• Presence of other concurrent malignancies. 2. History of prior anti-cancer treatments for the current diagnosis. 6. Study Endpoints

• Primary Endpoint: The Area Under the Receiver Operating Characteristic (ROC) curve (AUC) of the predictive model or risk-score framework for assessing patient-level treatment response to PD-1 inhibitor ± chemotherapy. Treatment response may be assessed using RECIST 1.1 and/or pathological response criteria, including tumor regression grade where applicable; for patients receiving neoadjuvant therapy followed by surgery, postoperative tumor regression grade and treatment failure before surgery may be classified according to the prespecified response-assessment rule.

• Secondary Endpoints: Additional efficacy metrics, including model sensitivity and specificity, Objective Response Rate (ORR), Duration of Response (DoR), Progression-Free Survival (PFS), Event-Free Survival (EFS), and Overall Survival (OS).

• Sample Size Calculation The sample size was calculated using a one-sample ROC curve analysis. Based on an expected AUC of 0.85 versus a null hypothesis threshold of AUC > 0.8, with a one-sided alpha of 0.05 and 80% power, the required sample size is 165 participants. Accounting for a 20% potential dropout rate, the study plans to enroll 200 participants for each of the four SCC subtypes, for a total of 800 participants.

• Study Procedures

• Baseline Period: Eligible patients who have signed the informed consent form will undergo baseline assessments before treatment initiation, including the collection of demographic and clinical data. Pre-treatment tumor tissue samples (archival paraffin-embedded blocks, biopsy slides, or H&E slides from within the last 6 months where available) and peripheral blood samples (collected within 28 days prior to treatment where available) will be collected according to standardized specimen-collection procedures.

• Follow-up Period: Patients will be followed up before treatment initiation and at weeks 4, 8, and 12 post-treatment where applicable. Follow-up visits will include collection of treatment details, updated medical history, imaging scans, physician-assessed tumor response (ORR), and pathological response assessment, including tumor regression grade where applicable.

• Survival Follow-up: After treatment discontinuation, all participants will enter a survival follow-up phase. Survival status and time-to-event outcomes, including PFS, EFS, and OS where applicable, will be collected via phone calls every 3 months until disease progression, death, loss to follow-up, withdrawal of consent, or study termination.

• Sample Collection and Management
• Tissue Samples: Residual pre-treatment biopsy tissue samples, left over from routine clinical diagnosis, will be collected. Samples will be formalin-fixed and paraffin-embedded (FFPE), sectioned, and stored at 4°C for subsequent H&E, PD-L1, multiplex immunofluorescence staining, and other tissue-based pathology evaluation where applicable.
• Blood Samples: Residual blood samples from routine clinical draws will be collected. Samples will be centrifuged to separate serum, which will then be stored at -80°C for future ELISA analysis.

• Statistical Analysis Plan
• Endpoint Analysis: Categorical variables and binary treatment-response outcomes will be analyzed using Chi-square or Fisher's exact tests. Model discrimination will be evaluated using ROC curves and AUC where applicable. Survival data (PFS, EFS, and OS where applicable) will be analyzed using the Kaplan-Meier method, with group comparisons performed using the Log-rank test. Multivariable analysis will be conducted using Cox proportional hazards models where appropriate.
• Missing Data: Multiple imputation will be used for randomly missing continuous variables. Missing key outcome variables (e.g., RECIST response or pathological response where applicable) will be handled conservatively according to the prespecified response-assessment rule; treatment failure before surgery may be classified as non-response where applicable.
• Subgroup Analyses: Pre-specified subgroup analyses will be performed based on factors such as PD-L1 expression level, smoking status, and treatment regimen.
• Sensitivity Analyses: Analyses will be conducted to test the robustness of the findings, including using different adjustment sets in multivariable models and analyzing the prospective cohort data exclusively for validation.

• Ethical Considerations This study will be conducted in full compliance with the principles of the Declaration of Helsinki and Good Clinical Practice (GCP) guidelines. The study protocol will be submitted to and approved by the Institutional Review Board (IRB)/Ethics Committee (EC) at each participating site before patient enrollment. All participants will undergo a thorough informed consent process, conducted by trained research staff in a private setting, and will be required to provide written informed consent before any study-related procedures are performed. Patient confidentiality will be strictly maintained.

Inclusion criteria

• Patients with pathologically confirmed esophageal squamous cell carcinoma (ESCC), head and neck squamous cell carcinoma (HNSCC), cervical squamous cell carcinoma (CSCC), or lung squamous cell carcinoma (LSCC), regardless of surgical eligibility
• For surgically eligible patients: Planned to receive neoadjuvant PD-1 inhibitor ± chemotherapy as first-line treatment
• For surgically ineligible patients: Planned to receive PD-1 inhibitor ± chemotherapy as first-line treatment
• Availability of pre-treatment biopsy tissue and baseline blood samples
• Capable of providing informed consent

Exclusion criteria

• Patients with concurrent other types of malignancies
• Patients who have already undergone prior antitumor therapy